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Purpose: Autosomal dominant optic atrophy (ADOA) is the most common form of hereditary optic neuropathy caused
by mutations in the optic atrophy 1 (OPA1) gene. It is characterized by insidious onset with a selective degeneration of
retinal ganglion cells, variable loss of visual acuity, temporal optic nerve pallor, tritanopia, and development of central,
paracentral, or cecocentral scotomas. Here we describe the clinical and molecular findings in a large Italian family with
ADOA.
Methods: Routine ophthalmologic examination and direct sequencing of all coding regions of the OPA1 gene were
performed. Further characterization of a new OPA1 gene insertion was performed by reverse transcription-PCR (RT–
PCR) of RNA from patients and control subjects.
Results: We identified an Alu-element insertion located in intron 7 of OPA1 causing an in-frame deletion of exon 8 in
18 family members.
Conclusions: The predicted consequence of this mutation is the loss of the guanosine triphosphatase (GTPase) activity
of OPA1. Alu insertions have been reported in the literature as causing human genetic disease. However, this is the first
report of a pathogenic OPA1 gene mutation resulting from an Alu insertion.
Autosomal  dominant  optic  atrophy  (ADOA;  OMIM
165500)  is  the  most  common  form  of  hereditary  optic
neuropathy, with an estimated prevalence between 1:10,000
and 1:50,000 in different populations [1]. It is characterized
by insidious onset with a selective degeneration of retinal
ganglion cells, variable loss of visual acuity, temporal optic
nerve  pallor,  tritanopia,  and  development  of  central,
paracentral, or cecocentral scotomas [2]. ADOA is inherited
in an autosomal dominant manner with high interfamilial and
intrafamilial  phenotypic  variability  and  incomplete
penetrance.
Mutations  in  the  optic  atrophy  1  (OPA1)  gene  (that
consists  of  30  coding  exons)  are  responsible  for
approximately 90% of cases. OPA1 encodes a large guanosine
triphosphatase  (GTPase),  implicated  in  the  formation  and
maintenance  of  the  mitochondrial  network  [3]  and  in
protection  against  apoptosis  by  segregating  cytochrome  c
inside the mitochondrial cristae [4]. OPA1 comprises a highly
basic  N-terminus,  a  dynamin  GTPase  domain,  and  a  C-
terminus. More than 200 pathogenic mutations have been
reported  in  the  literature  (see  the  eOPA1  database).  No
significant correlation has been observed between degree of
visual  impairment  and  location  or  type  of  mutation  [5].
Missense mutations in OPA1, however, leading to multiple
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mitochondrial DNA (mtDNA) deletions in skeletal muscle
and a mosaic defect of cytochrome c oxidase, were recently
found. In these cases the disorder presented with visual failure
and  optic  atrophy  in  childhood,  followed  by  Progressive
External  Ophthalmoplegia  (PEO),  ataxia,  deafness,  and
sensory-motor  neuropathy  in  adulthood.  Moreover,  some
cases show additional neurologic symptoms, the so-called
optic atrophy plus phenotypes [6].
METHODS
Family  study:  Twenty-eight  individuals  of  a  single  large
Italian  family  were  recruited  from  the  Department  of
Neurologic, Neurosurgical and Behavioral Sciences of Siena,
the Italian Union of the Blind of Siracusa and the Department
of Pediatric of Catania. There were 15 females and 13 males
ranging in age from 9 to 59 years. We use the term “family”
to indicate descendants of a multigenerational pedigree of
related  individuals  (Figure  1).  Autosomal  dominant
inheritance was indicated by multiple affected individuals in
each  generation.  All  patients  underwent  routine
ophthalmologic examination, including visual acuity, color
vision, manual visual field, slit-lamp examination, intraocular
pressure (IOP), and dilated fundoscopy. Clinical neurologic
examination and genetic analysis was also performed in all
patients.
Mutation analysis: After informed consent was obtained, 5 ml
of blood from the proband, his family members, and healthy
controls, was drawn into an ethylenediamine tetraacetic acid
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178(EDTA) sample tube and preserved (frozen). Genomic DNA
was extracted from blood samples using a QIAamp DNA
blood  kit  (Qiagen,  Limburg,  Netherlands).  All  30  coding
exons (comprising intron–exon boundaries) were amplified
by PCR using primers specific for OPA1 (Table 1). PCR
reactions  were  performed  in  25  μl  reaction  volumes
containing  100  ng  genomic  DNA,  10  pmol  forward  and
reverse  primers,  100  mM  dNTPs,  1U  DNA  polymerase
(Eurotaq DNA polymerase; Euroclone, Milan, Italy), 1.5 mM
MgSO4, 1× Reaction buffer, using a DNA thermal cycler
(PTC-200; MJ Research, Waltham, MA). The PCR products
of exon 8 were cloned into a PCR Cloning Vector pSC-A
using  the  Strata  Clone™  PCR  Cloning  Kit  (Agilent
Technologies,  Stratagene  Products  Division,  Santa  Clara,
CA). After purification of PCR products with QIAquick PCR
Purification kits (Qiagen), sequencing was performed using
the  automated  sequencer  ABI  3730  (Applied  Biosystems,
Foster City, CA).
RESULTS
Clinical  findings  in  carriers  of  mutations:  Neurologic
examination was unremarkable (Table 2). Ophthalmologic
examination revealed visual acuity ranging from 20/20 to less
than 20/200. Color vision was normal in two subjects, the
other 16 had different degrees of color sensitivity deficiency
(eight of them showed generalized color sensitivity deficit).
IOP with applanation was in the normal range in 11 patients
(not exceeding 19–20 mmHg); four subjects had IOP over
20 mmHg. One patient had high IOP (40 mmHg). Optic nerve
appearance was normal in two subjects, whereas nine showed
temporal pallor and six diffuse neurorim pallor.
Molecular studies: We sequenced the 30 coding exons of
OPA1  in  the  propositus.  We  did  not  find  any  known
pathogenic mutation, but amplification of exon 8 revealed a
hemizygous product of about 604 bp (Figure 2, A). Cloning
and sequencing of the longer band revealed an insertion of
about  325  bp.  Using  BLAST  and  Repeat  Masker  [7]  to
elucidate the nature of the inserted fragment, we identified 289
bp of the insert as belonging to AluYb8 (99.65% homology
with Alu Sb2). The Alu insert was composed of a 289-bp
fragment and contained a 25-bp poly(A) tail at its 3′ end with
perfect direct repeats of 17 bp flanking the insert (Figure
2B,C). In Figure 2C RNA polymerase III promoter (A and B
boxes)  and  the  consensus  target  site  sequence  are  also
indicated.  The  same  mutation  was  found  in  17  family
members (Figure 1); in ten subjects the mutation was absent,
and the analysis was not performed in the remaining family
members.  The  Alu  insertion  was  located  in  intron  7  of
OPA1, 21 bp upstream of exon 8, near the acceptor site (C.
784–21_22). The mutation caused the skipping of exon 8 in
mRNA (Figure 2D,E).
Figure 1. Pedigree diagram of the Autosomal Dominant Optic Atrophy (ADOA) family. The pedigree of a five-generation family shows
eighteen affected members. Solid squares mean male patients, open circles mean normal females, solid circles mean female patients, open
squares mean normal males, arrow means proband (V-3). Oblique lines through circles and squares represent deceased, vertical lines indicate
the  presence  of  the  mutation  in  two  unaffected  family  members  (IV-7  and  IV-10)  and  in  another  family  member  not  available  for
ophthalmological examination (V-15).
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Reverse  Transcriptase–PCR  analysis:  Peripheral  blood,
about 10 ml, was collected using vacutainer EDTA tubes
(Becton-Dickinson, Franklin Lakes, NJ) from the proband
(V-3, Figure 1), the proband’s mother (IV-8, Figure 1) and
three  healthy  controls.  Total  RNA  was  extracted  from
peripheral blood leucocytes using the LeukoLOCK™ Total
RNA Isolation System following the instruction supplied by
the manufacturer (Ambion, Austin, TX). The amount of total
RNA extracted from each blood sample was quantified using
the  NanoDrop  ND-1000  photometer  (NanoDrop
Technologies, Wilmington, DE). For each sample, 1.0 μg of
total  RNA  was  reverse  transcribed  with  Affinity  Script
(Agilent  Technologies)  using  oligo  dT  primers.  PCR
amplifications were performed with primers AF1 (5′-GAC
CAA CTT CAG GAA GAA CT-3′) and AR1 (5′-TGA GGA
CCT TCA CTC AGA GT-3′). After the purification of cDNA
products  with  QIAquick  PCR  Purification  kits  (Qiagen),
sequencing was performed using the automated sequencer
ABI 3730.DISCUSSION
In the case reported here, we found an unusual molecular
defect in OPA1 causing ADOA in a large Italian family. The
defect is the result of an Alu element insertion.
Alu sequences are the most frequent, short, interspersed
elements in the human genome, numbering 1.1 million copies
and more than 10% of the mass of the genome. Alu elements
are sequences of approximately 300 nucleotides flanked by
perfect direct repeats of the host sequence, consistent with
insertion into staggered nicks in the target DNA [8]. Alu and
other  repetitive  elements  have  had  great  influence  on  the
human genome and its evolution [9]. They influence mRNA
splicing,  RNA  editing,  and  protein  translation  [10].  Not
surprisingly, Alu insertions have been associated with several
human genetic disorders. A total of 26 L1 trans-driven Alu
insertions have so far been described as causes of diseases
[11].
In our case the Alu element was inserted in the antisense
direction with respect to OPA1. Alu element insertions in
introns can have strong effects on gene expression, especially
when inserted in the antisense direction. Five reports indicate
that  Alu  insertions  into  intronic  sequences  in  antisense
orientation and close to the affected exon (19–50 nucleotides)
cause the downstream exon to shift from constitutive splicing
to full exon skipping or alternative splicing. Three have been
found to cause skipping of downstream exons: one impairs
correct recognition of the splice acceptor site (F8 gene) [12],
while the other two may affect the branch site that is usually
very close to the end of the intron (NF1 and TNFRSF6 genes)
[13,14].  The  orientation  and  position  of  the  Alu  in  the
upstream intron was recently studied. Lev-Maor et al. shed
light on the positive and negative effects of Alu elements
inserted in antisense orientation immediately upstream of the
regulated exon [15].
In our case Alu insertion probably interferes with the
branch site leading to production of an alternatively spliced
mRNA lacking exon 8. Loss of this exon may be similar to
that  reported  for  Alu  element  insertion  in  NF1  and
TNFRSF6 genes.
A  consensus  target  site  is  probably  generated  in  the
antisense strand where integration of the retroposon begins:
the first 5′-gtAAAA-3′ hexanucleotides (3′CA↓TTTT 5′) of
the 17-bp target-site duplication flanking the Alu element
matches  one  of  the  more  frequent  consensus  sequences
perfectly [16]. The sense strand is nicked 17 bp from gtAAAA
[17].
TABLE 1. DNA SEQUENCE OF OLIGONUCLEOTIDES USED FOR POLYMERASE CHAIN REACTION (PCR).
Amplified
fragment Forward primer (5′-3′) Reverse primer (5′-3′)
PCR length
(bp)
Annealing
temperature °C
Promotor CATGGCTAGTACGGATGTAATT GGAGAAACTAACCACCATCA 250 55
Exon 1 TGTTTCCGTGACGGACTGAGTA CCTGAGAGTCACCTGCACATTT 330 56
Exon 2 TCCTTTGTACTGTTACCCTCTC CTAGTCCATGGTAGAGACACAA 530 54
Exon 3 CATTATTCTTAGTAGATTAATGTG AAACAGTTAGTGGCAGCTGTGG 340 56
Exon 4 GTAGGGTTGTCATGAGGATTAA CCTCCATGGTTCTTAAATTT 270 54
Exon 4b GAAATCTGAGATCTCAGACATC TGGTCTGCAATTTTATTTGCAAC 250 57
Exon 5 TCAGCTTAGGCTGTTGACATCAC CCAGAACTGCCACGTAATACCT 300 62
Exon 5b TCCCTAGCTTACATCTGTTCCT TGGCAGAAATGGCTGATTAGTG 270 57
Exon 6 GCAACAGGGAAATGATTGCCTT AGGTTCTATCATTACACCTTCC 410 56
Exon 7 AGGAGATATGACTTCAAGATTTTGG CCATCCTCCAAGCACATTAGGTT 350 57
Intron 7 AGGAGATATGACTTCAAGATTTTGG CATGTTTGTTAAGCTAGAACTG 900 56
Intron 7 CTGCAGTAAATCATGGCATGT GAGAGAGAAAGAGAGAGGACAG 650 52
Intron 7 CAGTGGATACTTAACCACCC GAGAACATCAAGAACTTCAG 450 54
Exon 8 CTCTTGACACATCTGTTATATT GCCTACATCTAGTATGTATA 270 52
Exon 9 CTCAGAGCAGCATTACAAATAGG AACACAATGAACAGGTCTCACTG 250 57
Exon 10 CAATGCAGTAGCCCTGTCTAGA GGCTAACGGTACAGCCTTCTTT 380 62
Exon 11 GATAGTTCTCGGGAGTTTGATC GCTCTACATATCTAGATAGCAGC 360 62
Exon 12 and 13 GTCTTATCTGAATGGATGAG GCAAAGCTTGGATTGCTAAAGAAG 420 57
Exon 14 CTTGCTATAATGTAGACACAGGG AAATCCCTATCACAGCTGGAGC 300 62
Exon 15 and 16 TAGGCAGCAGAGCAGGAATTCA CAGTTCAATTTAAGCTACTCTC 400 56
Exon 17 AGCACATTCGCAGACTTGGTGGTA GTATGGATGCCAAAGATTGCCAGC 260 68
Exon 18 CCACTTTAACCACTACATCTGG                    GAGATAACTGCTCCTAGAGATG 300 62
Exon 19 CCTCCCTTTGGTTATCTCTGAA GCCTATGAGCCAAGGCAACAATAAAT 270 54
Exon 20 CTTGACTGGTGCGATTTACAGG GAAAGATAGAGGCTGTGATGGG 430 60
Exon 21 CTGTTTGGCTTGAGCTCGTGTT TGAGGCTGATACCCCAGTATAC 430 62
Exon 22 GGGCCAGGAGAGAATCTCCACT TGGATGACTCCTTCACCACTGT 350 62
Exon 23 CTGCCTTCATATTGATATAGCAC ATTCCTGAGACTGGTCTAGAGC 300 54
Exon 24 TTTACCATATTCATAAGCCGGG TGTCAGCAAATGTACACGTGAC 450 60
Exon 25 CTTCTCAGTGTGGTTGATCAAC CCCCAGATGATCAAAGGACTTA 300 50
Exon 26 CTGGTTCTAGTAGTTGTATGTG AGCTACCACACCTGGCCAGTTT 350 56
Exon 27 GCACTTCCATTAAAGTGTATAGC ACAAATGGAAATGGGAAAGGTGG 420 62
Exon 28 AAGGTGGTATGGTGAGACTCAT TACAGCATAAGTGACAAGCAGG 350 62
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particular  peculiarities  since  ophthalmologic  variability
observed in our patients has also been described in other
common  OPA1  mutations.  Moreover,  the  presence  of  the
mutation  in  two  unaffected  family  members  suggests
incomplete  penetrance,  as  previously  reported  for  other
OPA1 gene mutations [18].
In  conclusion,  we  describe  an  AluYb8  [8]
retrotransposition event in an intron of the OPA1 gene leading
to exon skipping. The predicted consequence of this mutation
is the loss of the GTPase activity of OPA1. Alu insertions have
been  reported  in  the  literature  as  causing  human  genetic
disease.  However,  this  is  the  first  report  of  a  pathogenic
OPA1 gene mutation resulting from an Alu insertion.
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